DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Preoperative Cisplatin in Early Stage Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cisplatin

First Posted Date: 2005-09-08

Last Posted Date: 2016-08-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00148694

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Educational Interventions for Patients With DCIS

Not Applicable

Completed

Conditions: DCIS

First Posted Date: 2005-09-08

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 120

Registration Number: NCT00148655

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Cancer

First Posted Date: 2005-09-08

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00148707

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Capecitabine in Women With Operable Breast Cancer

Phase 2

Terminated

Conditions: Invasive Breast Carcinoma
Primary Invasive Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer
Stage I Breast Cancer

First Posted Date: 2005-09-08

Last Posted Date: 2015-11-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00148720

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00146601

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

Phase 2

Completed

Conditions: Graft Versus Host Disease
Hematologic Malignancies

First Posted Date: 2005-09-07

Last Posted Date: 2012-03-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 105

Registration Number: NCT00146614

Locations: 🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy

Completed

Conditions: Breast Neoplasms

First Posted Date: 2005-09-07

Last Posted Date: 2017-03-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 78

Registration Number: NCT00146536

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Stage IV Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 250

Registration Number: NCT00146549

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

Phase 2

Completed

Conditions: Hematologic Malignancies
Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Hodgkin's Disease

First Posted Date: 2005-09-05

Last Posted Date: 2012-01-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT00144703

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Graft Versus Host Disease
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Non-Hodgkin's Lymphoma
Hodgkin's Disease

First Posted Date: 2005-09-05

Last Posted Date: 2012-01-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00144677

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy